hemodynamics-based individualized antihypertensive therapy
Phase 3Small molecule
hemodynamics-based individualized antihypertensive therapy is one of 8 small molecule programs targeting Hypertensive. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Hypertensive
#DrugCompanyPhaseTrials
1Normodyne
AAlvogen Korea
Approved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ultomiris
AstraZenecaPhase 2
hemodynamics-based individualized antihypertensive therapy
TThe Third Xiangya Hospital of Central South University
Phase 3
Standard Medical Therapy
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Calcium Channel Blocker
MMinia University
Preclinical
Antihypertensive Medication
UUniversity of Alberta
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypertensive1 trial
Antihypertensive Drug Selection Based on Hemodynamic Phenotypes
Not yet recruiting·TThe Third Xiangya Hospital of Central South University·Phase 4·NCT07240909·240 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details